The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases
The NLRP3 inflammasome is a multiprotein complex that plays a pivotal role in regulating
the innate immune system and inflammatory signaling. Upon activation by PAMPs and …
the innate immune system and inflammatory signaling. Upon activation by PAMPs and …
Fenamates: Forgotten treasure for cancer treatment and prevention: Mechanisms of action, structural modification, and bright future
Fenamates as classical nonsteroidal anti‐inflammatory agents are widely used for relieving
pain. Preclinical studies and epidemiological data highlight their chemo‐preventive and …
pain. Preclinical studies and epidemiological data highlight their chemo‐preventive and …
Proteomics analysis of meclofenamic acid‐treated small cell lung carcinoma cells revealed changes in cellular energy metabolism for cancer cell survival
Small cell lung carcinoma (SCLC) is a highly aggressive cancer with low survival rate.
Although initial response to chemotherapy in SCLC patients is well‐rated, the treatments …
Although initial response to chemotherapy in SCLC patients is well‐rated, the treatments …
Investigation of the effect of meclofenamic acid on the proteome of LNCaP cells reveals changes in alternative polyadenylation and splicing machinery
Prostate cancer is the most common type of cancer among men, and there is still no
definitively effective drug treatment. Thus, the search for novel drug agents that may be used …
definitively effective drug treatment. Thus, the search for novel drug agents that may be used …
Synergistic effect of a nonsteroidal anti-inflammatory drug in combination with topotecan on small cell lung cancer cells
Background The topoisomerase I inhibitor topotecan (TPT) is used in the treatment of
recurrent small cell lung cancer (SCLC). However, the drug has a limited success rate and …
recurrent small cell lung cancer (SCLC). However, the drug has a limited success rate and …
Bicalutamide elicits renal damage by causing mitochondrial dysfunction via ROS damage and upregulation of HIF-1α
KC Chen, CR Chen, CY Chen, KY Tzou… - International journal of …, 2020 - mdpi.com
Combined androgen blockade using bicalutamide (Bic) is a therapeutic choice for treating
prostate cancer (PCa). However, even at regular clinical dosages, Bic frequently shows …
prostate cancer (PCa). However, even at regular clinical dosages, Bic frequently shows …
The Impact of Simultaneous Epigenetic and Epitranscriptomic Intervention in Breast Cancer Cells
S Yanar, AD Özkan, MGB Albayrak… - Istanbul Gelisim University …, 2024 - dergipark.org.tr
Aim: Breast cancer remains a significant cause of mortality worldwide, necessitating the
development of innovative therapeutic approaches. Epigenetic and epitranscriptomic …
development of innovative therapeutic approaches. Epigenetic and epitranscriptomic …
Prospected epigenetic moderators from natural sources and drug of class NSAIDS as effective treatment options to Prostate cancer
V Dubey, R Owusu-Apenten, S Tripathi… - Journal of Acute …, 2017 - journals.lww.com
Prostate cancer (PC) is one of the most common and leading cancer amongst the males all
around the world. Depending upon it long latency and cost involved in its management and …
around the world. Depending upon it long latency and cost involved in its management and …
[PDF][PDF] High fasting glucose, but not metabolic syndrome, is associated with elevated histologic aggressiveness in Mexican prostate cancer patients
R Garza-Guajardo, I Delgado-Enciso… - Int J Clin Exp …, 2016 - e-century.us
Prostate cancer and metabolic syndrome (MS) have high incidence rates in North America.
Some investigators have suggested that features of metabolic syndrome may be predictive …
Some investigators have suggested that features of metabolic syndrome may be predictive …
Meclofenamic acid inhibits the invasion and migration of LNCaP prostate carcinoma cells by regulating vimentin expression
A Kanlı, S Yanar - Acta Medica Nicomedia, 2022 - dergipark.org.tr
Objectives: Despite various studies to improve the early detection and development of novel
treatment agents, no significant progress has been made in the treatment of prostate cancer …
treatment agents, no significant progress has been made in the treatment of prostate cancer …